<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03198702</url>
  </required_header>
  <id_info>
    <org_study_id>POPB-TOX RB15.050</org_study_id>
    <nct_id>NCT03198702</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety of Early Intramuscular Botulinum Toxin Injections to Prevent Shoulder Deformity in Babies With Obstetrical Brachial Plexus Palsy</brief_title>
  <acronym>POPB-TOX</acronym>
  <official_title>Effectiveness and Safety of Early Intramuscular Botulinum Toxin Injections to Prevent Shoulder Deformity in Babies With Obstetrical Brachial Plexus Palsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In children population with obstetrical brachial plexus palsy (OBPP), shoulder
      musculoskeletal deformity is the main cause of morbidity, with a loss of range of shoulder
      motion, pain and a reduction in social participation. Some uncontrolled studies shows that
      early injections of botulinum toxin (BTI) in the internal shoulder rotator muscles (which
      cause the deformity) are one of the most promising treatment for the prevention of bony
      deformity.

      The main objective of this study will be the evaluation of the effectiveness of BTI in the
      internal shoulder rotator muscles at the age of 12 months in preventing an increase in
      posterior subluxation of the glenohumeral joint in babies with OBPP (evaluated at the ages of
      11 months and 18 months), compared to the Sham group.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2017</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>First group or &quot;toxin&quot; group: the babies will receive BOTOX injections at the age of 12 months in the shoulder muscles.
Second group or &quot;sham&quot; group:the babies receive the same procedure but no injection.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the percentage posterior migration of the humeral head measured on axial MRI slices between 11 (before the BTI carried out at 12 months) and 18 months of age (6 months post BTI).</measure>
    <time_frame>At 18 month age</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>compare the effectiveness of BTI with Sham procedure in preventing an increase in glenoid retroversion and three-dimensional deformity</measure>
    <time_frame>At 18 month age</time_frame>
    <description>With 2D glenoid changes measured on axial MRI and 3D glenoid version and migration of the humeral head measured on MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>compare the effectiveness of BTI with Sham procedure in the improvement of active and passive joint range of motion and upper limb function</measure>
    <time_frame>At 18 month age</time_frame>
    <description>By measurement of passive range of motion, Active Movement Scale and Assistive Hand Assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>confirm good clinical tolerance of BTI treatment</measure>
    <time_frame>At 18 month age</time_frame>
    <description>By measurement of the number of serious and non-serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluate the effects of BTI on trophicity, fibrosis and fatty infiltration of the injected muscles as well as muscle balance of the OBPP shoulder</measure>
    <time_frame>At 18 month age</time_frame>
    <description>Bu measurement of the degree of trophicity, fibrosis and fatty infiltration of the injected muscles (supraspinous, infraspinous, teres minor, subscapularis, teres major, pectoralis major, deltoid and latissimus dorsi)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>determine if the treatment changes the frequency and type of surgical interventions in the long term</measure>
    <time_frame>every years on 2 years old to 10 years old</time_frame>
    <description>the number and type of surgical interventions undergone by the children in each group will be recorded during routine medical follow-up (as in usual practice) until the child's 10th birthday following unblinding (9 years and 6 months after the BTI).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Obstetrical Brachial Plexus Palsy</condition>
  <arm_group>
    <arm_group_label>Toxin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The babies receive a botulinum toxin type A injection at the age of 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The babies receive a simulated injection procedure at the age of 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin type A injection</intervention_name>
    <description>A total of 8UI/kg will be injected in the internal shoulder rotator muscles: 2UI/kg in the sub scapular muscle, 3UI/kg in the pectoralis major muscle and 3UI/kg in the teres major/latissimus dorsi muscle.</description>
    <arm_group_label>Toxin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sham</intervention_name>
    <description>The injection is mimed, the procedure is the same as the botulinum toxin injection.</description>
    <arm_group_label>Sham group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female babies with unilateral OBPP

          -  Age between 10 and 11 months

          -  Presenting one of 2 risk factors for posterior subluxation of the humeral head (10°
             less passive external ROM of the affected shoulder compared with the contralateral
             shoulder and/or a score strictly less than 6 on the AMS for shoulder external rotation
             and abduction, elbow flexion or supination)

          -  Signature of the consent form by (the) parent(s) over the age of majority

        Exclusion Criteria:

          -  Bilateral OBPP

          -  Microsurgery or secondary muscle surgery planned between 12 and 18 months of age

          -  Contraindications to the use of botulinum toxin

          -  Contraindications to MRI

          -  MRI not possible in the Paediatric Day Hospital setting because of contraindications
             to the sedation protocol or due to organisational constraints

          -  Parents inapt to provide consent for the participation of their child

          -  Parents under the age of 18 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Months</minimum_age>
    <maximum_age>11 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sylvain Brochard, Pr</last_name>
    <phone>(+33) 02 98 22.33.73</phone>
    <email>sylvain.brochard@chu-brest.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49103</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mickaël DINOMAIS, Dr</last_name>
      <phone>02.41.35.15.15</phone>
    </contact>
    <investigator>
      <last_name>Mickaël DINOMAIS, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvain BROCHARD, Pr</last_name>
      <phone>02 98 22 33 73</phone>
    </contact>
    <contact_backup>
      <last_name>Chritelle PONS, Dr</last_name>
      <phone>02 98 22 33 73</phone>
    </contact_backup>
    <investigator>
      <last_name>Sylvain BROCHARD, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christelle PONS, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institue Régionnal de Réadaptation Centre de Réadaptation pour enfant</name>
      <address>
        <city>Flavigny-sur-Moselle</city>
        <zip>54630</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Emilie RUMILLY, Dr</last_name>
      <phone>03 83 85 85 85</phone>
    </contact>
    <investigator>
      <last_name>Emilie RUMILLY, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mélanie PORTE, Dr</last_name>
      <phone>04 66 68 68 68</phone>
    </contact>
    <investigator>
      <last_name>Mélanie PORTE, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philippe VIOLAS, Dr</last_name>
      <phone>02 99 28 43 21</phone>
    </contact>
    <investigator>
      <last_name>Philippe VIOLAS, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU St Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent GAUTHERON, Dr</last_name>
      <phone>04 77 82 80 00</phone>
    </contact>
    <investigator>
      <last_name>Vincent GAUTHERON, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2017</study_first_submitted>
  <study_first_submitted_qc>June 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2017</study_first_posted>
  <last_update_submitted>July 4, 2017</last_update_submitted>
  <last_update_submitted_qc>July 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>physiotherapy</keyword>
  <keyword>children</keyword>
  <keyword>shoulder deformation</keyword>
  <keyword>obstetrical brachial plexus palsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paralysis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

